GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Santen Pharmaceutical Co Ltd (OTCPK:SNPHY) » Definitions » Inventory-to-Revenue

Santen Pharmaceutical Co (Santen Pharmaceutical Co) Inventory-to-Revenue : 0.58 (As of Mar. 2024)


View and export this data going back to 2010. Start your Free Trial

What is Santen Pharmaceutical Co Inventory-to-Revenue?

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Santen Pharmaceutical Co's Average Total Inventories for the quarter that ended in Mar. 2024 was $307 Mil. Santen Pharmaceutical Co's Revenue for the three months ended in Mar. 2024 was $528 Mil. Santen Pharmaceutical Co's Inventory-to-Revenue for the quarter that ended in Mar. 2024 was 0.58.

Santen Pharmaceutical Co's Inventory-to-Revenue for the quarter that ended in Mar. 2024 declined from Dec. 2023 (0.59) to Dec. 2023 (0.58)

A decrease in the Inventory-to-Revenue from one quarter to next indicates that one of these is occurring:

1. investment in inventory is shrinking in relation to revenue
2. revenue are increasing
No matter which situation is causing the reduction in the Inventory-to-Revenue, either one suggests that business's inventory levels and its cash flow are effectively managed.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Santen Pharmaceutical Co's Days Inventory for the three months ended in Mar. 2024 was 132.61.

Inventory Turnover measures how fast the company turns over its inventory within a year. Santen Pharmaceutical Co's Inventory Turnover for the quarter that ended in Mar. 2024 was 0.69.


Santen Pharmaceutical Co Inventory-to-Revenue Historical Data

The historical data trend for Santen Pharmaceutical Co's Inventory-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Santen Pharmaceutical Co Inventory-to-Revenue Chart

Santen Pharmaceutical Co Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Inventory-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.14 0.16 0.16 0.15 0.15

Santen Pharmaceutical Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Inventory-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.48 0.58 0.61 0.59 0.58

Competitive Comparison of Santen Pharmaceutical Co's Inventory-to-Revenue

For the Drug Manufacturers - General subindustry, Santen Pharmaceutical Co's Inventory-to-Revenue, along with its competitors' market caps and Inventory-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Santen Pharmaceutical Co's Inventory-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Santen Pharmaceutical Co's Inventory-to-Revenue distribution charts can be found below:

* The bar in red indicates where Santen Pharmaceutical Co's Inventory-to-Revenue falls into.



Santen Pharmaceutical Co Inventory-to-Revenue Calculation

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Santen Pharmaceutical Co's Inventory-to-Revenue for the fiscal year that ended in Mar. 2024 is calculated as

Inventory-to-Revenue (A: Mar. 2024 )
=Average Total Inventories / Revenue
=( (Total Inventories (A: Mar. 2023 ) + Total Inventories (A: Mar. 2024 )) / count ) / Revenue (A: Mar. 2024 )
=( (294.409 + 288.249) / 2 ) / 2015.537
=291.329 / 2015.537
=0.14

Santen Pharmaceutical Co's Inventory-to-Revenue for the quarter that ended in Mar. 2024 is calculated as

Inventory-to-Revenue (Q: Mar. 2024 )
=Average Total Inventories / Revenue
=( (Total Inventories (Q: Dec. 2023 ) + Total Inventories (Q: Mar. 2024 )) / count ) / Revenue (Q: Mar. 2024 )
=( (325.896 + 288.249) / 2 ) / 528.185
=307.0725 / 528.185
=0.58

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Santen Pharmaceutical Co  (OTCPK:SNPHY) Inventory-to-Revenue Explanation

An increase in Inventory-to-Revenue from one quarter to the next indicates that one of the following is happening:

1. investment in inventory is growing more rapidly than revenue
2. revenue are dropping
No matter which situation is causing the problem, an increase in the Inventory-to-Revenue may signal an oncoming cash flow problem.

Likewise, a decrease in the Inventory-to-Revenue from one quarter to next indicates that one of these is occurring:

1. investment in inventory is shrinking in relation to revenue
2. revenue are increasing
No matter which situation is causing the reduction in the Inventory-to-Revenue, either one suggests that business's inventory levels and its cash flow are effectively managed.

More Related Terms:

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Santen Pharmaceutical Co's Days Inventory for the three months ended in Mar. 2024 is calculated as:

Days Inventory=Average Total Inventories (Q: Mar. 2024 )/Cost of Goods Sold (Q: Mar. 2024 )*Days in Period
=307.0725/211.295*365 / 4
=132.61

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

Santen Pharmaceutical Co's Inventory Turnover for the quarter that ended in Mar. 2024 is calculated as

Inventory Turnover=Cost of Goods Sold (Q: Mar. 2024 ) / Average Total Inventories (Q: Mar. 2024 )
=211.295 / 307.0725
=0.69

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Santen Pharmaceutical Co Inventory-to-Revenue Related Terms

Thank you for viewing the detailed overview of Santen Pharmaceutical Co's Inventory-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Santen Pharmaceutical Co (Santen Pharmaceutical Co) Business Description

Traded in Other Exchanges
Address
Grand Front Osaka Tower A, 4-20 Ofuka-cho, Kita-ku, Osaka, JPN, 530-8552
Santen Pharmaceutical Co Ltd is a drug manufacturing company that focuses on ophthalmic products. The company reports two primary operating segments: prescription ophthalmic pharmaceuticals and other. The pharmaceuticals segment includes over-the-counter pharmaceuticals, while the other segment includes medical devices. The vast majority of Santen's revenue is derived from its prescription ophthalmic pharmaceuticals segment, which manufactures and distributes prescription and OTC pharmaceuticals. Most of Santen's sales are generated in Japan, followed by other Asian countries.

Santen Pharmaceutical Co (Santen Pharmaceutical Co) Headlines

From GuruFocus

Matthews Japan Fund Comments on Santen Pharmaceutical

By Sydnee Gatewood Sydnee Gatewood 04-23-2020

Matthews Japan Fund 1st-Quarter Commentary

By Sydnee Gatewood Sydnee Gatewood 04-23-2020